Actively Recruiting
Implementing a National Biobank of PD With WGS and Functional Assessment of Polygenic Inheritance by iPSC Technology
Led by IRCCS San Raffaele · Updated on 2026-03-30
230
Participants Needed
1
Research Sites
161 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The genetic complexity and heterogeneity of the sporadic forms of Parkinson's disease (PD) are posing a formidable challenge to disentangle their direct molecular causes. To advance this research, we plan to coordinate our local biorepositories of PD biological specimens creating a standardized and integrated national resource. In this framework, we plan to collect more samples from additional sporadic PD cases and to extend the sampling to patients with REM sleep behavior disease. We plan a large campaign of whole genome sequencing including about 200 patients to identify rare genomic variants plausibly associated with these diseases. In addition, we will standardize the generation and quality control of iPSC lines to make available to the scientific community. Finally, we will combine iPSC technology and gene editing to functionally assess the relative impact of rare variants in coding regions inherited together as a polygenic trait previously identified in selected sporadic PD cases
CONDITIONS
Official Title
Implementing a National Biobank of PD With WGS and Functional Assessment of Polygenic Inheritance by iPSC Technology
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Presence of at least 2 of the 4 cardinal Parkinson's disease signs (tremor, rigidity, bradykinesia, onset asymmetric), with tremor or bradykinesia required
- No atypical symptoms such as early postural instability, freezing, cognitive impairment, hallucinations, involuntary movements, or vertical gaze paralysis
- No confirmed secondary parkinsonism causes such as focal lesions, drugs, or toxic substances
- Documented response or adequate therapeutic attempt to L-dopa or dopamine agonists
- Diagnosis of idiopathic REM sleep behavior disorder (RBD) by international classification criteria (ICSD-3)
You will not qualify if you...
- Presence of pre-existing psychiatric conditions
- Having neurodegenerative neurological diseases like multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, neuromuscular diseases, or epilepsy
- Diagnosis of dementia
- Having depression
- Prolonged use of anxiolytics, antidepressants, antipsychotics, hypnotics, or cognitive stimulants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS San Raffaele
Milan, Italy, Italy, 20132
Actively Recruiting
Research Team
V
Vania Broccoli, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here